ArticleDrug testing and analysis2026
Phase I Metabolism of Novel Phencyclidine Derivative 3-Cl-PCP: In Vitro Studies With Pooled Human Liver Microsomes and Investigation of a Post-Mortem Case.
Article in Drug testing and analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phase I metabolism of the methadone analog methiodone (IC-26) in pooled human liver microsomes and its detection in seven authentic human cases.Archives of toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Assessing fatalities linked to new psychoactive substances (NPS) often remains challenging. This study investigates a fatal intoxication involving the novel phencyclidine derivative 3-chloro-phencyclidine (3-Cl-PCP), analyzing its phase I metabolism aided by pooled human liver microsomes (pHLMs) and supported by in silico models. Postmortem samples (bile, urine, cardiac and femoral blood, and gastric contents) and three syringes were collected from a fatal intoxication case. Quantification was performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). In vitro metabolism studies employed pHLM incubation, with metabolites tentatively identified by liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). To evaluate phase II metabolism, urine and bile samples were measured with and without β-glucuronidase treatment. 3-Cl-PCP concentrations ranged from 610 ng/mL in cardiac blood to 830 ng/mL in femoral blood. Higher levels were detected in urine (1200 ng/mL) and bile (4300 ng/mL). Seven phase I metabolites were tentatively identified in vitro and postmortem, primarily involving hydroxylation of the cyclohexyl (M1-M3) and piperidine (M4-M5) rings. Additionally, piperidine ring-opened carboxyl (M6) and ring-opened alcohol (M7) metabolites were tentatively identified. Post-enzyme urine analysis revealed extensive glucuronidation of metabolites M1-M5, with M4 (hydroxyl piperidine) showing the highest abundance. Bile showed elevated abundance of unconjugated metabolites, particularly M6. Metabolites M4-M7 were detected in all investigated matrices. Unchanged 3-Cl-PCP predominantly accumulated in bile. Urine analysis should prioritize the parent compound along with the metabolites hydroxy cyclohexyl (M3), hydroxy piperidine (M4), and piperidine ring-opened carboxyl (M6) and should include a prior β-glucuronidase cleavage step.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.